This is a Study Evaluating the Efficacy and Safety of LTG-001 for Acute Pain After Surgical Removal of Impacted Third Molars
Trial details
- Registry ID
- NCT06774625
- Phase
- Phase 2
The FDA approved Suzetrigine on 30 Jan 2025.
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| This is a Study Evaluating the Efficacy and Safety of LTG-001 for Acute Pain After Surgical Removal of Impacted Third MolarsNCT06774625 | Latigo Biotherapeutics | Phase 2 | Completed | 2025-08-08Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2025-01-30Day | Suzetrigine | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA219209", "applicant_as_listed_by_fda": "VERTEX PHARMS INC", "brand_names": ["JOURNAVX"], "active_ingredients": ["SUZETRIGINE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20250130", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |